EN DE
Watch ProKidney Corp. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ProKidney Corp. (PROK) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of ProKidney Corp. stock $0.50, price $1.11, that is 55.0% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PC ProKidney Corp. logo Thin data Nov 11, 2026

ProKidney Corp.

PROK · US
Very expensive, weak quality

Our calculation puts a fair price 55% below what the stock costs today.

Mixed Growth (revenue YoY +1075.0 %/yr in USD)
Negative equity (buybacks among others)
Insiders sold $1.1M (6M)
Revenue last quarter 32% below a year ago.
Fair value $0.5000 · Strongly overvalued
Quality 32/100
Negative free cash flow
Trails peers (1/4)
Narrow moat 12/100
Thin data
Estimate
Watch ProKidney Corp. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.78 $0.5109 Fair Value $0.5000 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $0.5109 – $13.78 · fair‑value band $0.3800 – $0.6300 · the $1.11 price screens above the $0.5000 fair value. As of Nov 11, 2026.

Follow ProKidney in your weekly email

Every Wednesday you see whether ProKidney is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.

Show moreShow less

The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.

The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Stock analysis

ProKidney Corp. (PROK) currently trades at $1.11, while our estimate is $0.5000, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.3800 (bear) to $0.6300 (bull), the price of $1.11 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

ProKidney Corp. reported revenue of $893K in FY2025 versus $0 in FY2021. Reported net income was −$69.0M in FY2025.

Key figures

Market cap $459M Small · EPS (TTM) $−0.5500 · Return on equity −59.0% · Return on assets (EBIT) −58.6% (5-year average) · Operating margin −32,249% · Revenue (TTM) $818K · Revenue growth (YoY) −32.1% · Free cash flow −$135M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 60% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −55%, PROK screens richer than that median.

Fair Value

Bear $0.3800 Fair Value $0.5000 Bull $0.6300
Price $1.11 · Downside -55.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $1.1M and none bought.

  • SaleBrian JG PereiraDirector2× since Nov 12, 2025: 1,514,326 shares, avg. $1.95$3.0MAug 20, 2026

Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 22/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PROK screens overvalued: fair value 55% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ProKidney Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −55.0% · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −20.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) −32.1% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PROK
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PROK
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PROK
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PROK
argenx SE ARGX $971.55 $908.40 −7% vs PROK
CSL Limited CSL A$201.68 A$181.40 −10% vs PROK
Moderna, Inc MRNA $250.83 $158.70 −37% vs PROK
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PROK
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PROK
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PROK

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ProKidney Corp.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ProKidney Corp. Fair Value". https://www.fairvalue-calculator.com/stock/PROK

Frequently asked questions

Is ProKidney Corp. (PROK) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $0.5000 versus a price of $1.11, about 55% lower (overvalued).
What is the fair value of PROK?
Our estimate for ProKidney Corp. is $0.5000 (as of Nov 11, 2026), built from audited fundamentals. The current price: $1.11.
What is the quality score of PROK?
ProKidney Corp. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ProKidney Corp. (PROK)?
Our calculated price target is the estimate of $0.5000 (as of Nov 11, 2026). Cautious scenario $0.3800, optimistic scenario $0.6300. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ProKidney Corp. stock forecast for 2026?
Our estimate puts fair value at $0.5000, about 55% lower versus a price of $1.11 (overvalued). Cautious scenario $0.3800, optimistic scenario $0.6300. The calculation is refreshed regularly with new filings.
What is the revenue of ProKidney Corp. (PROK)?
ProKidney Corp. reported trailing-twelve-month revenue of about $818K (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of ProKidney Corp. (PROK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ProKidney Corp. it is $0.5000 per share (as of Nov 11, 2026), against a price of $1.11.
Is ProKidney Corp. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, PROK trades above its calculated fair value: price $1.11, fair value $0.5000, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PROK?
No. The price is what the market pays today ($1.11); the fair value is what the company's own numbers justify ($0.5000). For ProKidney Corp. the two are $0.6100 per share apart. That gap is exactly why we show both numbers side by side.
How much is ProKidney Corp. worth?
The market values ProKidney Corp. at about $459M (market capitalisation, as of Nov 11, 2026). Per share that is $1.11; our models calculate a fair value of $0.5000 per share.
What do the bullish and bearish scenarios say about PROK?
Our models span a range for ProKidney Corp.: cautious scenario $0.3800, base $0.5000, optimistic $0.6300 per share (as of Nov 11, 2026, price $1.11). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ProKidney Corp. (PROK)?
Balance-sheet figures for ProKidney Corp. (as of Nov 11, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is PROK from its 52-week high?
ProKidney Corp. trades at $1.11, about 60% below its 52-week high of $2.80 and 4% above the low of $1.07 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5000 is for.
Which stocks are comparable to ProKidney Corp.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ProKidney Corp. stock attractive at the current price?
The data as of Nov 11, 2026: price $1.11, calculated fair value $0.5000 (−55%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. ProKidney Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ProKidney Corp. (PROK)?
The closing price on Nov 10, 2026 was $1.11. Our estimate is $0.5000, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ProKidney Corp. right now?
The price sits above even our optimistic bull case ($0.6300). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ProKidney Corp.

How large is the market capitalisation of ProKidney Corp. (PROK)?
The market capitalisation of ProKidney Corp. is $459M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ProKidney Corp. (PROK)?
Earnings per share at ProKidney Corp. are $−0.5500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ProKidney Corp. (PROK)?
The return on equity (ROE) of ProKidney Corp. is −59.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ProKidney Corp. (PROK)?
On an EBIT basis the return on assets of ProKidney Corp. is −58.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ProKidney Corp. (PROK)?
The operating margin of ProKidney Corp. is −32,249% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ProKidney Corp. (PROK)?
Revenue at ProKidney Corp. is growing −32.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ProKidney Corp. (PROK) generate?
The free cash flow of ProKidney Corp. is −$135M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ProKidney Corp. (PROK) hold?
ProKidney Corp. holds more cash than debt, $105M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ProKidney Corp. in the live analysis

One click puts ProKidney Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.